Resigratinib (KIN-3248) is a FGFR tyrosine kinase inhibitor, with antineoplastic effect.
References:
[1]. Franovic, et al. Treatment of cancer with an FGFR kinase inhibitor. World Intellectual Property Organization, WO2023107979 A1 2023-06-15.
Resigratinib (KIN-3248) is a FGFR tyrosine kinase inhibitor, with antineoplastic effect.
References:
[1]. Franovic, et al. Treatment of cancer with an FGFR kinase inhibitor. World Intellectual Property Organization, WO2023107979 A1 2023-06-15.